Breast cancer precursors revisited: Molecular features and progression pathways

Histopathology

Volumn 57, Issue 2, 2010, Pages 171-192

  Lopez Garcia, Maria A ^a,b   Geyer, Felipe C ^b   Lacroix Triki, Magali ^a,c   Marchió, Caterina ^d   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

breast cancer; carcinoma in situ; comparative genomic hybridization; microarrays; molecular pathology

Indexed keywords

APOCRINE LESION; BREAST CANCER; BREAST HYPERPLASIA; BREAST LESION; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER RISK; COLUMNAR CELL LESION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; INTRADUCTAL CARCINOMA; LOBULAR CARCINOMA IN SITU; PLEOMORPHIC LOBULAR CARCINOMA IN SITU; PRIORITY JOURNAL; RADICAL SCAR; REVIEW;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPLASIA; KERATINS; METAPLASIA; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; PRECANCEROUS CONDITIONS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955837344     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03568.x     Document Type: Review

References (193)

1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 2009 360 790 800.
2. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 2009 220 263 280.
3. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat. Rev. Clin. Oncol. 2009 6 718 730.
4. Reis-Filho JS, Simpson PT, Gale T, Lakhani SR. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol. Res. Pract. 2005 201 713 725.
5. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J. Pathol. 2005 205 248 254.
6. Hicks J, Krasnitz A, Lakshmi B et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res. 2006 16 1465 1479.
7. Natrajan R, Lambros MB, Rodriguez-Pinilla SM et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin. Cancer Res. 2009 15 2711 2722.
8. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med. 1985 312 146 151.
9. Dupont WD, Parl FF, Hartmann WH et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993 71 1258 1265.
10. Jensen RA, Dupont WD, Page DL. Diagnostic criteria and cancer risk of proliferative breast lesions. J. Cell. Biochem. Suppl. 1993 17G 59 64.
11. Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer 1990 66 1326 1335.
12. Page DL, Dupont WD. Proliferative breast disease: diagnosis and implications. Science 1991 253 915 916.
13. Page DL, Dupont WD. Indicators of increased breast cancer risk in humans. J. Cell. Biochem. Suppl. 1992 16G 175 182.
14. Page DL, Dupont WD. Benign breast diseases and premalignant breast disease. Arch. Pathol. Lab. Med. 1998 122 1048 1050.
15. Tavassoli FA, Devilee P, eds. Tumours of the breast.
16. Wellings SR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. J. Natl Cancer Inst. 1973 50 1111 1118.
17. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J. Natl Cancer Inst. 1975 55 231 273.
18. Wellings SR, Jentoft VL. Organ cultures of normal, dysplastic, hyperplastic, and neoplastic human mammary tissues. J. Natl Cancer Inst. 1972 49 329 338.
19. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988 319 525 532.
20. Celis JE, Moreira JM, Gromova I et al. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol. Oncol. 2007 1 97 119.
21. Allred DC, Wu Y, Mao S et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin. Cancer Res. 2008 14 370 378.
22. Bonner RF, Emmert-Buck M, Cole K et al. Laser capture microdissection: molecular analysis of tissue. Science 1997 278 1481 1483.
23. Buerger H, Mommers EC, Littmann R et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J. Pathol. 2001 194 165 170.
24. Roylance R, Gorman P, Harris W et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res. 1999 59 1433 1436.
25. Ma XJ, Salunga R, Tuggle JT et al. Gene expression profiles of human breast cancer progression. Proc. Natl Acad. Sci. USA 2003 100 5974 5979.
26. Balleine RL, Webster LR, Davis S et al. Molecular grading of ductal carcinoma in situ of the breast. Clin. Cancer Res. 2008 14 8244 8252.
27. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 2006 98 262 272.
28. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000 406 747 752.
29. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001 98 10869 10874.
30. Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006 7 96.
31. Natrajan R, Weigelt B, Mackay A et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res. Treat. 2010 121 575 589.
32. Nikolsky Y, Sviridov E, Yao J et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 2008 68 9532 9540.
33. Lacroix M, Toillon RA, Leclercq G. Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocr. Relat. Cancer 2004 11 497 522.
34. Loo LW, Grove DI, Williams EM et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res. 2004 64 8541 8549.
35. Melchor L, Honrado E, Garcia MJ et al. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 2008 27 3165 3175.
36. Rennstam K, Ahlstedt-Soini M, Baldetorp B et al. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res. 2003 63 8861 8868.
37. Chin K, DeVries S, Fridlyand J et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006 10 529 541.
38. Abdel-Fatah TM, Powe DG, Hodi Z et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am. J. Surg. Pathol. 2007 31 417 426.
39. Abdel-Fatah TM, Powe DG, Hodi Z et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am. J. Surg. Pathol. 2008 32 513 523.
40. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985 55 2698 2708.
41. Washington C, Dalbegue F, Abreo F, Taubenberger JK, Lichy JH. Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas. Am. J. Pathol. 2000 157 323 329.
42. Geyer FC, Kushner YB, Lambros MB et al. Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma. Histopathology 2009 55 732 743.
43. Shin SJ, Simpson PT, Da Silva L et al. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. Am. J. Surg. Pathol. 2009 33 496 504.
44. Lakhani SR, Chaggar R, Davies S et al. Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J. Pathol. 1999 189 496 503.
45. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996 274 2057 2059.
46. Larson PS, de las Morenas A, Bennett SR, Cupples LA, Rosenberg CL. Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am. J. Pathol. 2002 161 283 290.
47. Larson PS, de las Morenas A, Cupples LA, Huang K, Rosenberg CL. Genetically abnormal clones in histologically normal breast tissue. Am. J. Pathol. 1998 152 1591 1598.
48. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum. Pathol. 2007 38 1105 1122.
49. Cleton-Jansen AM, Buerger H, Haar N et al. Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer 2004 41 109 116.
50. Tsai YC, Lu Y, Nichols PW et al. Contiguous patches of normal human mammary epithelium derived from a single stem cell: implications for breast carcinogenesis. Cancer Res. 1996 56 402 404.
51. Novelli M, Cossu A, Oukrif D et al. X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. Proc. Natl Acad. Sci. USA 2003 100 3311 3314.
52. Moinfar F, Man YG, Arnould L et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res. 2000 60 2562 2566.
53. Campbell I, Polyak K, Haviv I. Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Res. 2009 69 6765 6768 discussion 9.
54. Holliday C, Rummel S, Hooke JA et al. Genomic instability in the breast microenvironment? A critical evaluation of the evidence. Expert Rev. Mol. Diagn. 2009 9 667 678.
55. Farrand K, Jovanovic L, Delahunt B et al. Loss of heterozygosity studies revisited: prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability. J. Mol. Diagn. 2002 4 150 158.
56. Bodian CA, Perzin KH, Lattes R, Hoffmann P, Abernathy TG. Prognostic significance of benign proliferative breast disease. Cancer 1993 71 3896 3907.
57. Kamel OW, Kempson RL, Hendrickson MR. In situ proliferative epithelial lesions of the breast. Pathology (Phila) 1992 1 65 102.
58. Rosen P, ed. Rosen's breast pathology, 2nd edn.
59. Andersen JA, Gram JB. Radial scar in the female breast. A long-term follow-up study of 32 cases. Cancer 1984 53 2557 2560.
60. Anderson TJ, Battersby S. Radial scars of benign and malignant breasts: comparative features and significance. J. Pathol. 1985 147 23 32.
61. Fisher ER, Palekar AS, Kotwal N, Lipana N. A nonencapsulated sclerosing lesion of the breast. Am. J. Clin. Pathol. 1979 71 240 246.
62. Jacobs TW, Byrne C, Colditz G, Connolly JL, Schnitt SJ. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N. Engl. J. Med. 1999 340 430 436.
63. Sloane JP, Mayers MM. Carcinoma and atypical hyperplasia in radial scars and complex sclerosing lesions: importance of lesion size and patient age. Histopathology 1993 23 225 231.
64. Manfrin E, Remo A, Falsirollo F, Reghellin D, Bonetti F. Risk of neoplastic transformation in asymptomatic radial scar. Analysis of 117 cases. Breast Cancer Res. Treat. 2008 107 371 377.
65. Iqbal M, Shoker BS, Foster CS et al. Molecular and genetic abnormalities in radial scar. Hum. Pathol. 2002 33 715 722.
66. Denley H, Pinder SE, Tan PH et al. Metaplastic carcinoma of the breast arising within complex sclerosing lesion: a report of five cases. Histopathology 2000 36 203 209.
67. O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology 2008 52 3 10.
68. Selim AG, Wells CA. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors. J. Clin. Pathol. 1999 52 838 841.
69. Shoker BS, Jarvis C, Clarke RB et al. Abnormal regulation of the oestrogen receptor in benign breast lesions. J. Clin. Pathol. 2000 53 778 783.
70. Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 1996 5 29 32.
71. Jones C, Damiani S, Wells D et al. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am. J. Pathol. 2001 158 207 214.
72. Selim AG, Ryan A, El-Ayat G, Wells CA. Loss of heterozygosity and allelic imbalance in apocrine metaplasia of the breast: microdissection microsatellite analysis. J. Pathol. 2002 196 287 291.
73. Lininger RA, Zhuang Z, Man Y et al. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast. Mod. Pathol. 1999 12 1083 1089.
74. Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005 24 4660 4671.
75. Lakhani SR, Slack DN, Hamoudi RA et al. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab. Invest. 1996 74 129 135.
76. O'Connell P, Pekkel V, Fuqua SA et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J. Natl Cancer Inst. 1998 90 697 703.
77. Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res. 2003 5 313 319.
78. Aubele MM, Cummings MC, Mattis AE et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn. Mol. Pathol. 2000 9 14 19.
79. Jones C, Merrett S, Thomas VA, Barker TH, Lakhani SR. Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast. J. Pathol. 2003 199 152 156.
80. Boecker W, Buerger H, Schmitz K et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J. Pathol. 2001 195 415 421.
81. Otterbach F, Bankfalvi A, Bergner S et al. Cytokeratin 56 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000 37 232 240.
82. Boecker W, Moll R, Dervan P et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J. Pathol. 2002 198 458 467.
83. Simpson PT, Gale T, Reis-Filho JS et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am. J. Surg. Pathol. 2005 29 734 746.
84. Arriola E, Lambros MB, Jones C et al. Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Lab. Invest. 2007 87 75 83. (Pubitemid 44973656)
85. Fraser JL, Raza S, Chorny K, Connolly JL, Schnitt SJ. Columnar alteration with prominent apical snouts and secretions: a spectrum of changes frequently present in breast biopsies performed for microcalcifications. Am. J. Surg. Pathol. 1998 22 1521 1527.
86. Goldstein NS, O'Malley BA. Cancerization of small ectatic ducts of the breast by ductal carcinoma in situ cells with apocrine snouts: a lesion associated with tubular carcinoma. Am. J. Clin. Pathol. 1997 107 561 566.
87. Feeley L, Quinn CM. Columnar cell lesions of the breast. Histopathology 2008 52 11 19.
88. Azzopardi JG. Problems in breast pathology.
89. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann. Intern. Med. 2005 143 446 457.
90. McLaren BK, Gobbi H, Schuyler PA et al. Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study. Am. J. Surg. Pathol. 2005 29 105 108.
91. Oyama T, Maluf H, Koerner F. Atypical cystic lobules: an early stage in the formation of low-grade ductal carcinoma in situ. Virchows Arch. 1999 435 413 421.
92. Vincent-Salomon A. [Columnar lesions: a frequent diagnosis in breast pathology]. Ann. Pathol. 2003 23 593 596.
93. Pinder SE, Reis-Filho JS. Non-operative breast pathology: columnar cell lesions. J. Clin. Pathol. 2007 60 1307 1312.
94. Schnitt SJ. The diagnosis and management of pre-invasive breast disease: flat epithelial atypia - classification, pathologic features and clinical significance. Breast Cancer Res. 2003 5 263 268.
95. Schnitt SJ, Vincent-Salomon A. Columnar cell lesions of the breast. Adv. Anat. Pathol 2003 10 113 124.
96. Dabbs DJ, Carter G, Fudge M et al. Molecular alterations in columnar cell lesions of the breast. Mod. Pathol. 2006 19 344 349.
97. Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ('clinging ductal carcinoma in situ'): a simulator of normal mammary epithelium. Cancer 2000 88 2072 2081.
98. Carley AM, Chivukula M, Carter GJ, Karabakhtsian RG, Dabbs DJ. Frequency and clinical significance of simultaneous association of lobular neoplasia and columnar cell alterations in breast tissue specimens. Am. J. Clin. Pathol. 2008 130 254 258.
99. Brandt SM, Young GQ, Hoda SA. The 'Rosen Triad': tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions. Adv. Anat. Pathol. 2008 15 140 146.
100. Hanby AM, Hughes TA. In situ and invasive lobular neoplasia of the breast. Histopathology 2008 52 58 66.
101. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978 42 737 769.
102. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary carcinoma. Am. J. Pathol. 1941 17 9.
103. Page DL, Dupont WD, Rogers LW. Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk. Hum. Pathol. 1988 19 201 207.
104. Simpson PT, Gale T, Fulford LG, Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res. 2003 5 258 262.
105. Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch. Pathol. Lab. Med. 1998 122 1053 1055.
106. Reis-Filho JS, Pinder SE. Non-operative breast pathology: lobular neoplasia. J. Clin. Pathol. 2007 60 1321 1327.
107. Lu YJ, Osin P, Lakhani SR et al. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res. 1998 58 4721 4727.
108. Mastracci TL, Shadeo A, Colby SM et al. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferation in the breast. Genes Chromosomes Cancer 2006 45 1007 1017.
109. Page DL, Schuyler PA, Dupont WD et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003 361 125 129.
110. Lakhani SR, Audretsch W, Cleton-Jensen AM et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? Eur. J. Cancer 2006 42 2205 2211.
111. Schnitt SJ, Morrow M. Lobular carcinoma in situ: current concepts and controversies. Semin. Diagn. Pathol. 1999 16 209 223.
112. Droufakou S, Deshmane V, Roylance R et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int. J. Cancer 2001 92 404 408.
113. Sarrio D, Moreno-Bueno G, Hardisson D et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int. J. Cancer 2003 106 208 215.
114. Derksen PW, Liu X, Saridin F et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006 10 437 449.
115. Vos CB, Cleton-Jansen AM, Berx G et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br. J. Cancer 1997 76 1131 1133. (Pubitemid 27448007)
116. Hwang ES, Nyante SJ, Yi Chen Y et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004 100 2562 2572.
117. Nyante SJ, Devries S, Chen YY, Hwang ES. Array-based comparative genomic hybridization of ductal carcinoma in situ and synchronous invasive lobular cancer. Hum. Pathol. 2004 35 759 763.
118. Morandi L, Marucci G, Foschini MP et al. Genetic similarities and differences between lobular in situ neoplasia (LN) and invasive lobular carcinoma of the breast. Virchows Arch. 2006 449 14 23.
119. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005 103 2481 2484.
120. Tavassoli FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 1990 65 518 529.
121. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982 49 751 758.
122. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J. Clin. Pathol. 1995 48 611 615.
123. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J. Pathol. 1995 175 195 201.
124. Amari M, Suzuki A, Moriya T et al. LOH analyses of premalignant and malignant lesions of human breast: frequent LOH in 8p, 16q, and 17q in atypical ductal hyperplasia. Oncol. Rep. 1999 6 1277 1280.
125. Larson PS, de las Morenas A, Cerda SR et al. Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors. J. Pathol. 2006 209 307 316.
126. Gong G, DeVries S, Chew KL et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin. Cancer Res. 2001 7 2410 2414.
127. Buerger H, Otterbach F, Simon R et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast - evidence of multiple genetic pathways. J. Pathol. 1999 187 396 402.
128. Clement PB, Azzopardi JG. Microglandular adenosis of the breast - a lesion simulating tubular carcinoma. Histopathology 1983 7 169 180.
129. Rosen PP. Microglandular adenosis. A benign lesion simulating invasive mammary carcinoma. Am. J. Surg. Pathol. 1983 7 137 144.
130. Tavassoli FA, Bratthauer GL. Immunohistochemical profile and differential diagnosis of microglandular adenosis. Mod. Pathol. 1993 6 318 322.
131. Koenig C, Dadmanesh F, Bratthauer GL, Tavassoli FA. Carcinoma arising in microglandular adenosis: an immunohistochemical analysis of 20 intraepithelial and invasive neoplasms. Int. J. Surg. Pathol. 2000 8 303 315.
132. Rosenblum MK, Purrazzella R, Rosen PP. Is microglandular adenosis a precancerous disease? A study of carcinoma arising therein. Am. J. Surg. Pathol. 1986 10 237 245.
133. Khalifeh IM, Albarracin C, Diaz LK et al. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am. J. Surg. Pathol. 2008 32 544 552.
134. Acs G, Simpson JF, Bleiweiss IJ et al. Microglandular adenosis with transition into adenoid cystic carcinoma of the breast. Am. J. Surg. Pathol. 2003 27 1052 1060.
135. Tavassoli FA, Norris HJ. Microglandular adenosis of the breast. A clinicopathologic study of 11 cases with ultrastructural observations. Am. J. Surg. Pathol. 1983 7 731 737.
136. Simpson PT, Reis-Filho JS, Lambros MB et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J. Pathol. 2008 215 231 244.
137. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum. Pathol. 1992 23 655 662.
138. Middleton LP, Palacios DM, Bryant BR et al. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am. J. Surg. Pathol. 2000 24 1650 1656.
139. Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod. Pathol. 2002 15 1044 1050.
140. Chen YY, Hwang ES, Roy R et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am. J. Surg. Pathol. 2009 33 1683 1694.
141. Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am. J. Surg. Pathol. 2008 32 1721 1726.
142. Vargas AC, Lakhani SR, Simpson PT. Pleomorphic lobular carcinoma of the breast: molecular pathology and clinical impact. Future Oncol. 2009 5 233 243.
143. Reis-Filho JS, Simpson PT, Jones C et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J. Pathol. 2005 207 1 13.
144. Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum. Pathol. 1992 23 1167 1171.
145. Hughes LL, Wang M, Page DL et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2009 27 5319 5324.
146. Vincent-Salomon A, Lucchesi C, Gruel N et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin. Cancer Res. 2008 14 1956 1965.
147. Hannemann J, Velds A, Halfwerk JB et al. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res. 2006 8 R61.
148. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat. Rev. Cancer 2007 7 659 672.
149. Weigelt B, Glas AM, Wessels LF et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl Acad. Sci. USA 2003 100 15901 15905.
150. Weigelt B, Hu Z, He X et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005 65 9155 9158.
151. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 2005 5 591 602.
152. Buerger H, Otterbach F, Simon R et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J. Pathol. 1999 189 521 526.
153. Robanus-Maandag EC, Bosch CA, Kristel PM et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J. Pathol. 2003 201 75 82.
154. Porter D, Lahti-Domenici J, Keshaviah A et al. Molecular markers in ductal carcinoma in situ of the breast. Mol. Cancer Res. 2003 1 362 375.
155. Fazzari MJ, Greally JM. Epigenomics: beyond CpG islands. Nat. Rev. Genet. 2004 5 446 455.
156. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002 21 5462 5482.
157. Ai L, Kim WJ, Kim TY et al. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 2006 66 7899 7909.
158. Lehmann U, Langer F, Feist H et al. Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol. 2002 160 605 612.
159. Pasquali L, Bedeir A, Ringquist S et al. Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. Cancer Lett. 2007 257 136 144.
160. Umbricht CB, Evron E, Gabrielson E et al. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001 20 3348 3353.
161. Hu M, Yao J, Cai L et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 2005 37 899 905.
162. Allinen M, Beroukhim R, Cai L et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004 6 17 32. (Pubitemid 38903159)
163. Hu M, Yao J, Carroll DK et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008 13 394 406.
164. Man YG, Sang QX. The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the 'protease-centered' hypothesis. Exp. Cell Res. 2004 301 103 118.
165. Zhang RR, Man YG, Vang R et al. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. Breast Cancer Res. 2003 5 R151 R156.
166. Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications. Am. J. Surg. Pathol. 2009 33 227 232.
167. Maley CC, Galipeau PC, Finley JC et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 2006 38 468 473.
168. Mackay A, Tamber N, Fenwick K et al. A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res. Treat. 2009 118 481 498.
169. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006 10 515 527.
170. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 2008 14 5158 5165.
171. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008 10 R65.
172. Buerger H, Schmidt H, Beckmann A et al. Genetic characterisation of invasive breast cancer: a comparison of CGH and PCR based multiplex microsatellite analysis. J. Clin. Pathol. 2001 54 836 840.
173. Buerger H, Simon R, Schafer KL et al. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol. Pathol. 2000 53 118 121.
174. Natrajan R, Lambros MB, Geyer FC et al. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer 2009 48 351 365.
175. Roylance R, Gorman P, Papior T et al. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene 2006 25 6544 6553.
176. Melchor L, Honrado E, Huang J et al. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Clin. Cancer Res. 2007 13 7305 7313.
177. Andre F, Job B, Dessen P et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res. 2009 15 441 451.
178. Tsuda H, Takarabe T, Fukutomi T, Hirohashi S. der(16)t(1;16)der(1;16) in breast cancer detected by fluorescence in situ hybridization is an indicator of better patient prognosis. Genes Chromosomes Cancer 1999 24 72 77.
179. Flagiello D, Gerbault-Seureau M, Sastre-Garau X et al. Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer 1998 23 300 306.
180. Geyer FC, Lopez-Garcia MA, Lambros MB, Reis-Filho JS. Genetic characterisation of breast cancer and implications for clinical management. J. Cell Mol. Med. 2009 Sep 14. [Epub ahead of print] DOI: 10.1111/j.1582-4934.2009. 00906.
181. Chin SF, Teschendorff AE, Marioni JC et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 2007 8 R215.
182. Bergamaschi A, Kim YH, Wang P et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006 45 1033 1040.
183. Adelaide J, Finetti P, Bekhouche I et al. Integrated profiling of basal and luminal breast cancers. Cancer Res. 2007 67 11565 11575.
184. Tavassoli FA. Breast pathology: rationale for adopting the ductal intraepithelial neoplasia (DIN) classification. Nat. Clin. Pract. Oncol. 2005 2 116 117.
185. Tavassoli FA. Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia. Mod. Pathol. 1998 11 140 154.
186. Martel M, Barron-Rodriguez P, Tolgay Ocal I, Dotto J, Tavassoli FA. Flat DIN 1 (flat epithelial atypia) on core needle biopsy: 63 cases identified retrospectively among 1,751 core biopsies performed over an 8-year period (1992-1999). Virchows Arch. 2007 451 883 891.
187. Jones BM, Bradbeer JW. The presentation and progress of macroscopic breast cysts. Br. J. Surg. 1980 67 669 671.
188. Nielsen M, Christensen L, Andersen J. Radial scars in women with breast cancer. Cancer 1987 59 1019 1025.
189. Sanders ME, Page DL, Simpson JF et al. Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies. Cancer 2006 106 1453 1461.
190. Boulos FI, Dupont WD, Simpson JF et al. Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study. Cancer 2008 113 2415 2421.
191. McLaren BK, Schuyler PA, Sanders ME et al. Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy. Cancer 2006 107 1227 1233.
192. Gao Y, Niu Y, Wang X, Wei L, Lu S. Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. J. Mol. Med. 2009 87 145 152.
193. Lakhani SR, Collins N, Sloane JP, Stratton MR. Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin. Mol. Pathol. 1995 48 M74 M78.